CA
NZ
UK
AU
IND
US
Few clinical-stage names have travelled as far below their former levels as Biodexa Pharmaceuticals plc (NASDAQ:BDRX). The Welsh biopharmaceutical company, trading in the United States through American Depositary Shares, now sits under a dollar with aMarket Valuemeasured in the hundreds of thousands, a striking …
● Few names carry more weight in medical technology than Becton, Dickinson and Company, and the stock has spent September 2026 near the center of investor attention on the New York Stock Exchange.
Few established med-tech names have had a rougher stretch than Accuray Incorporated (NASDAQ:ARAY). The maker of the CyberKnife and TomoTherapy radiation-oncology systems has watched its stock sink well below $1, and in early September 2026 the shares slipped further.
A stock quoted at a hundredth of a penny rarely rewards a search for the "next catalyst," and Arrayit Corporation (OTC:ARYC) is a textbook example. The microarray-diagnostics company once pitched itself as a life-sciences innovator, but it stopped filing audited financial reports years ago, …
A former blank-check company now chasing a niche in drug delivery, Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is one of the harder micro-caps to pin down. The shares trade near $8.61 on a marketCapitalizationof roughly $12 million, a combination that points to a very …
Few clinical-stage biotechs have swung as violently as aTyr Pharma, Inc (NASDAQ:ATYR). Once a multi-dollar stock built on hopes for its lead immunology candidate, aTyr now trades below $1 after a pivotal trial stumbled in 2025.
Some tickers on the U.S. over-the-counter market are less "stocks" in the conventional sense than dormant corporate shells trading in fractions of a penny. AVVAA World Health Care Products, Inc. (OTC:AVVH) sits firmly in that category. Quoted around $0.0015 with a market value near …
AirSculpt Technologies (NASDAQ: AIRS) has become a case study in how quickly investor enthusiasm can cool for a consumer-facing medical business. The body-contouring specialist, once valued as a high-growth aesthetics play, now trades near $2.61 with a marketCapitalizationof roughly $188 million, a fraction of …
Aligos Therapeutics, Inc (NASDAQ:ALGS) has spent 2026 stacking up clinical and commercial milestones even as its shares remain squarely in small-cap territory. The Nasdaq-listed, clinical-stage biopharmaceutical is best known for its hepatitis B program, and this year it added a marquee licensing deal and …
● A quiet uptick has kept Amarin on investors' radar as the cardiovascular-drug maker works to prove there is life beyond its once-blockbuster U.S.
Please wait processing your request...